is a pediatric application. Phenobarbital is a barbiturate used to treat focal and generalized epilepsy. Since the end of marketing of the oral solution KANEURON in 2017, phenobarbital tablets remain the only available dosage form. Therefore, developing an oral phenobarbital solution for pediatric use is essential to fulfilling clinical needs. A new formulation of phenobarbital with hydroxypropyl-β-cyclodextrins (HPBCD) was developed, and the physicochemical stability of the solution was evaluated.
Louise Parrenne, Zoé Ribier et al – Greater Paris University Hospitals – AP-HP
See the full article here: Formulation and stability study of an oral paediatric phenobarbital 1% solution containing hydroxypropyl-β-cyclodextrins